L-oreal allergy, also known as food allergy, is an extremely rare condition that affects 2-3 percent of the population and can be deadly. It also mostly affects children. What I will assume that you do not know, but will hopefully one day understand, is that the ingredients on a food-allergy warning label are just a few examples of the far greater number of allergen ingredients that may appear on your plates, whether you know it or not. In fact, an estimated 85-90 percent of allergens (about two-thirds) in foods are just unnamed ingredients, and of these, most may not even be known allergens, at least in the granular sense.
It seems then, that if you are allergic to something, you are likely to have also become immune to more than one substance at the same time. This is because a single allergen can cause a cascade of signaling in the immune system that drives response after response and results in a complete and total immune response, no matter which one it is. This immunological state is known as autoimmunity, which then becomes a real and present risk for food-allergic patients.
Atypical immune diseases such as anaphylaxis and anaphylactoid anaphylaxis are caused by the inability of the body to suppress an existing autoimmunity.
In recognition of this dire state, the Food and Drug Administration recently received a petition from AstraZeneca and German biotechnology company Boehringer Ingelheim requesting that an anaphylaxis-inducing antibody be considered for expedited regulatory review because it might help lower the mortality rate associated with food-allergic reactions.
The FDA granted the application designation as an “expressly contraindicated” drug for use in adults with anaphylaxis who are allergic to certain allergens in the oral route of administration. The presentation of the drug also applies to adults with a severe anaphylaxis. It does not apply to children.